Exact Sciences Corp.(NASDAQ: EXAS) today announced that a new peer-reviewed study of Cologuard®, a multi-target stool DNA test (MT-sDNA), confirms ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments Short Sales

Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12 October 30, 2015 8:32 AM New Study Bolsters Cologuard’s Performance in Detecting Colorectal Cancer and Ability to Improve Access to ScreeningOctober 28, 2015 2:43 PM